Drug Search Results
More Filters [+]

Cetilistat

Alternative Names: cetilistat, atl-962, atl962, atl 962
Latest Update: 2024-05-01
Latest Update Note: PubMed Publication

Product Description

Cetilistat is a novel, orally active, gastrointestinal and pancreatic lipase inhibitor.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/24524093/)

Mechanisms of Action: LIP Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: India | Japan

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cetilistat

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Obesity

Phase 2: Type 2 Diabetes|Obesity

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

JapicCTI-080658

P3

Completed

Obesity

2010-07-31

Dose-Ranging Study of ATL-962 in Obese Patients with Type II Diabetes

P2

Completed

Obesity

2005-10-19

JapicCTI-090858

P3

Completed

Obesity

None

ATL-962/175/CL

P2

Completed

Type 2 Diabetes|Obesity

None

Recent News Events